WEKO3
アイテム
{"_buckets": {"deposit": "10b22341-5f2c-4edc-b39d-03a4370a67de"}, "_deposit": {"created_by": 1, "id": "81542", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "81542"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00081542", "sets": ["28"]}, "author_link": ["915397", "915394", "915395", "915398", "915399", "915393", "915396", "915400"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2020-02-05", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) are genetically modified G-protein coupled receptors that are activated by physiologically inert designer drugs. Two types of muscarinic-based designer receptor, such as hM3Dq (excitatory) and hM4Di (inhibitory), are widely used and remotely modulate the neural activity of a target cell population expressing a \"designer receptor\" by systemic delivery of a designer drug (CNO). \n We have shown that positron emission tomography (PET) with [11C]clozapine enables us to monitor the hM4Di expression and the agonist dose–occupancy relationship that provides critical information for successful chemogenetic silencing (Nagai et al., 2016). However, previous designer-drugs suffer from low selectivity and poor metabolic stability.\n Here we developed a novel ligand, deschloroclozapine (DCZ), served a dual purpose in chemogenetics: (1) as a selective compound for visualization of DREADD expression in vivo by PET and (2) as a selective agonist for muscarinic-based DREADDs.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "第6回 CiNet Conference Brain-Machine Interface - Medical Engineering based on Neuroscience -", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "永井, 裕司"}], "nameIdentifiers": [{"nameIdentifier": "915393", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "宮川, 尚久"}], "nameIdentifiers": [{"nameIdentifier": "915394", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "堀, 由紀子"}], "nameIdentifiers": [{"nameIdentifier": "915395", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "南本, 敬史"}], "nameIdentifiers": [{"nameIdentifier": "915396", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagai, Yuji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "915397", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyakawa, Naohisa", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "915398", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hori, Yukiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "915399", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Minamimoto, Takafumi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "915400", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "A novel chemogenetic agnoist \"Deschloroclozapine\" selectively visualizes and activates chemogenetic receptors in non-human primates", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A novel chemogenetic agnoist \"Deschloroclozapine\" selectively visualizes and activates chemogenetic receptors in non-human primates"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/81542", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-01-05"}, "publish_date": "2021-01-05", "publish_status": "0", "recid": "81542", "relation": {}, "relation_version_is_last": true, "title": ["A novel chemogenetic agnoist \"Deschloroclozapine\" selectively visualizes and activates chemogenetic receptors in non-human primates"], "weko_shared_id": -1}
A novel chemogenetic agnoist "Deschloroclozapine" selectively visualizes and activates chemogenetic receptors in non-human primates
https://repo.qst.go.jp/records/81542
https://repo.qst.go.jp/records/81542fc5ad68e-b615-4792-8299-d749e30199bc
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-01-05 | |||||
タイトル | ||||||
タイトル | A novel chemogenetic agnoist "Deschloroclozapine" selectively visualizes and activates chemogenetic receptors in non-human primates | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
永井, 裕司
× 永井, 裕司× 宮川, 尚久× 堀, 由紀子× 南本, 敬史× Nagai, Yuji× Miyakawa, Naohisa× Hori, Yukiko× Minamimoto, Takafumi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) are genetically modified G-protein coupled receptors that are activated by physiologically inert designer drugs. Two types of muscarinic-based designer receptor, such as hM3Dq (excitatory) and hM4Di (inhibitory), are widely used and remotely modulate the neural activity of a target cell population expressing a "designer receptor" by systemic delivery of a designer drug (CNO). We have shown that positron emission tomography (PET) with [11C]clozapine enables us to monitor the hM4Di expression and the agonist dose–occupancy relationship that provides critical information for successful chemogenetic silencing (Nagai et al., 2016). However, previous designer-drugs suffer from low selectivity and poor metabolic stability. Here we developed a novel ligand, deschloroclozapine (DCZ), served a dual purpose in chemogenetics: (1) as a selective compound for visualization of DREADD expression in vivo by PET and (2) as a selective agonist for muscarinic-based DREADDs. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 第6回 CiNet Conference Brain-Machine Interface - Medical Engineering based on Neuroscience - | |||||
発表年月日 | ||||||
日付 | 2020-02-05 | |||||
日付タイプ | Issued |